These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 8305744)
1. The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma. Hosokawa T; Muraishi A; Rothman VL; Papale M; Tuszynski GP Oncol Res; 1993; 5(4-5):183-9. PubMed ID: 8305744 [TBL] [Abstract][Full Text] [Related]
2. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Tuszynski GP; Nicosia RF Lab Invest; 1994 Feb; 70(2):228-33. PubMed ID: 7511188 [TBL] [Abstract][Full Text] [Related]
3. Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Incardona F; Lewalle JM; Morandi V; Lambert S; Legrand Y; Foidart JM; Legrand C Cancer Res; 1995 Jan; 55(1):166-73. PubMed ID: 7805029 [TBL] [Abstract][Full Text] [Related]
4. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion. Albo D; Berger DH; Rothman VL; Tuszynski GP J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848 [TBL] [Abstract][Full Text] [Related]
5. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion. Albo D; Berger DH; Tuszynski GP J Surg Res; 1998 Apr; 76(1):86-90. PubMed ID: 9695745 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. López-Alemany R; Longstaff C; Hawley S; Mirshahi M; Fábregas P; Jardí M; Merton E; Miles LA; Félez J Am J Hematol; 2003 Apr; 72(4):234-42. PubMed ID: 12666133 [TBL] [Abstract][Full Text] [Related]
7. Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction. Clezardin P; Serre CM; Trzeciak MC; Drouin J; Delmas PD Cancer Res; 1991 May; 51(10):2621-7. PubMed ID: 1708697 [TBL] [Abstract][Full Text] [Related]
8. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Albo D; Arnoletti JP; Castiglioni A; Granick MS; Solomon MP; Rothman VL; Tuszynski GP Biochem Biophys Res Commun; 1994 Sep; 203(2):857-65. PubMed ID: 8093068 [TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. Albo D; Tuszynski GP J Surg Res; 2004 Jul; 120(1):21-6. PubMed ID: 15172186 [TBL] [Abstract][Full Text] [Related]
10. Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity. Sid B; Langlois B; Sartelet H; Bellon G; Dedieu S; Martiny L Int J Biochem Cell Biol; 2008; 40(9):1890-900. PubMed ID: 18321763 [TBL] [Abstract][Full Text] [Related]
11. Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway. Shih YW; Wu PF; Lee YC; Shi MD; Chiang TA J Agric Food Chem; 2009 May; 57(9):3490-9. PubMed ID: 19326946 [TBL] [Abstract][Full Text] [Related]
12. The role of thrombospondin-1 in tumor progression and angiogenesis. Tuszynski GP; Nicosia RF Bioessays; 1996 Jan; 18(1):71-6. PubMed ID: 8593167 [TBL] [Abstract][Full Text] [Related]
13. Thrombospondin, a potentiator of tumor cell metastasis. Tuszynski GP; Gasic TB; Rothman VL; Knudsen KA; Gasic GJ Cancer Res; 1987 Aug; 47(15):4130-3. PubMed ID: 3607754 [TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Qian X; Wang TN; Rothman VL; Nicosia RF; Tuszynski GP Exp Cell Res; 1997 Sep; 235(2):403-12. PubMed ID: 9299165 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. Tuszynski GP; Rothman VL; Papale M; Hamilton BK; Eyal J J Cell Biol; 1993 Jan; 120(2):513-21. PubMed ID: 8421063 [TBL] [Abstract][Full Text] [Related]
16. Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells. Sasaki CY; Lin H; Passaniti A J Cell Physiol; 1999 Oct; 181(1):1-13. PubMed ID: 10457348 [TBL] [Abstract][Full Text] [Related]
17. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma. Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Alonso DF; Tejera AM; Farias EF; Bal de Kier Joffe E; Gomez DE Anticancer Res; 1998; 18(6A):4499-504. PubMed ID: 9891516 [TBL] [Abstract][Full Text] [Related]
19. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945 [TBL] [Abstract][Full Text] [Related]
20. The failure to reconstitute the second extracellular matrix-integrin-cytoskeleton system in human endothelial cells on type V collagen. Yamamoto K; Yamamoto M Artery; 1994; 21(2):76-93. PubMed ID: 7695484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]